The effects of aprotinin on thromboelastography with three different activators

被引:25
作者
Avidan, MS [1 ]
Da Fonseca, J [1 ]
Parmar, K [1 ]
Alcock, E [1 ]
Ponte, J [1 ]
Hunt, BJ [1 ]
机构
[1] Guys Kings & St Thomas Med Sch, Dept Anaesthesiol, Dept Haematol, London, England
关键词
D O I
10.1097/00000542-200111000-00021
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Thromboelastography is used for assessment of hemostasis. Adherence to thromboelastography-guided algorithms and aprotinin administration each decrease bleeding and blood product usage after cardiac surgery. Aprotinin, through inhibition of kallikrein, causes prolongation of the celite-activated clotting time and the activated partial thromboplastin ratio. The aim of this study was to assess the effects of aprotinin on the thromboelastography trace. Methods. Three activators were used in the thromboelastography: celite (which is widely established), kaolin, and tissue factor. Assessment was performed on blood from volunteers and from patients before and after cardiac surgery. Results: The tissue factor-activated thromboelastography trace was unaffected by the addition of aprotinin. When celite and kaolin were used as activators in the presence of aprotinin, the reaction time (time to clot formation) of the thromboelastography trace was prolonged (P < 0.0001) and the maximum amplitude (clot strength) was decreased (P < 0.05). With celite as an activator, the addition of aprotinin decreased (P < 0.05) the thromboelastography a angle (rate of clot extension). The reaction time of the celite-activated trace correlated with the activated partial thromboplastin ratio (P < 0.01). The reaction time of the tissue factor-activated trace correlated with the international normalized ratio (P < 0.01). Conclusion: The thromboelastography trace is altered in the presence of aprotinin when celite and kaolin are used as activators but not when tissue factor is the activator.
引用
收藏
页码:1169 / 1174
页数:6
相关论文
共 21 条
[1]  
AVIDAN MS, 2000, BR J ANAESTH, V85
[2]  
BOISCLAIR MD, 1993, BLOOD, V82, P3350
[3]  
CARSON JL, 1988, LANCET, V1, P727
[4]   The effect of aprotinin on thrombelastography in vitro [J].
Chalkiadis, GA ;
Gibbs, NM .
ANAESTHESIA AND INTENSIVE CARE, 1996, 24 (05) :552-554
[5]   APROTININ - A REVIEW OF ITS PHARMACOLOGY AND THERAPEUTIC EFFICACY IN REDUCING BLOOD-LOSS ASSOCIATED WITH CARDIAC-SURGERY [J].
DAVIS, R ;
WHITTINGTON, R .
DRUGS, 1995, 49 (06) :954-983
[6]  
DeHert SG, 1996, EUR J ANAESTH, V13, P463
[7]   APROTININ PROLONGS WHOLE-BLOOD ACTIVATED PARTIAL THROMBOPLASTIN TIME BUT NOT WHOLE-BLOOD PROTHROMBIN TIME IN PATIENTS UNDERGOING CARDIAC-SURGERY [J].
DESPOTIS, GJ ;
ALSOUFIEV, A ;
GOODNOUGH, LT ;
LAPPAS, DG .
ANESTHESIA AND ANALGESIA, 1995, 81 (05) :919-924
[8]   EFFECT OF CELITE AND KAOLIN ON ACTIVATED CLOTTING TIME IN THE PRESENCE OF APROTININ - ACTIVATED CLOTTING TIME IS REDUCED BY BINDING OF APROTININ TO KAOLIN [J].
DIETRICH, W ;
JOCHUM, M .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1995, 109 (01) :177-178
[9]   CELITE AND KAOLIN PRODUCE DIFFERING ACTIVATED CLOTTING TIMES DURING CARDIOPULMONARY BYPASS UNDER APROTININ THERAPY [J].
FEINDT, P ;
SEYFERT, UT ;
VOLKMER, I ;
STRAUB, U ;
GAMS, E .
THORACIC AND CARDIOVASCULAR SURGEON, 1994, 42 (04) :218-221
[10]  
HUNT BJ, 1992, CIRCULATION, V86, P410